Compass Therapeutics, Inc. (CMPX)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-06) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-05) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-05) · 99.1 | 8-K (2026-01-06) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-05) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-11) · 99.1 · 99.2 · 99.3 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-08) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-02-27) · 99.1 | 8-K (2025-01-08) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-12) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-12) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-13) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-21) · 99.1 | 8-K (2024-01-05) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-09) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Condensed Consolidated Balance Sheets | — |
|
| Condensed Consolidated Balance Sheets (current Period Unaudited) | — |
|
| Condensed Consolidated Balance Sheets (current Period Unaudited) (P) | — |
|
| Condensed Consolidated Balance Sheets (P) | — |
|
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||
| Condensed Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Changes In Stockholders' Equity | — |
|
| Condensed Consolidated Statements of Cash Flows | ||
| Condensed Consolidated Statements of Stockholders' Equity (P) | ||
| Consolidated Statements of Changes In Stockholders' Equity (P) | — |
|
| Notes | ||
| Award Timing Disclosure | — |
|
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Note 1 | ||
| Note 1 - Nature of Business and Basis of Presentation | — |
|
| Note 10 | ||
| Note 10 - Basic and Diluted Net Loss Per Share | — |
|
| Note 11 | ||
| Note 11 - License, Research and Collaboration Agreements | — |
|
| Note 12 | ||
| Note 12 - Segment Information | — |
|
| Note 13 | ||
| Note 14 | — |
|
| Note 15 | — |
|
| Note 2 | ||
| Note 2 - Summary of Significant Accounting Policies | — |
|
| Note 3 | ||
| Note 3 - Fair Value Measurements | — |
|
| Note 4 | ||
| Note 4 - Marketable Securities | — |
|
| Note 5 | ||
| Note 5 - Property and Equipment | — |
|
| Note 6 | ||
| Note 6 - Accrued Expenses | — |
|
| Note 7 | ||
| Note 7 - Commitments and Contingencies | — |
|
| Note 8 | ||
| Note 8 - Stock-based Compensation | — |
|
| Note 9 | ||
| Note 9 - Stockholders' Equity | — |
|